Folgen
Marc Gitzinger
Marc Gitzinger
CEO BioVersys AG
Bestätigte E-Mail-Adresse bei bioversys.com - Startseite
Titel
Zitiert von
Zitiert von
Jahr
Self-sufficient control of urate homeostasis in mice by a synthetic circuit
C Kemmer, M Gitzinger, M Daoud-El Baba, V Djonov, J Stelling, ...
Nature biotechnology 28 (4), 355-360, 2010
3122010
A synthetic mammalian gene circuit reveals antituberculosis compounds
W Weber, R Schoenmakers, B Keller, M Gitzinger, T Grau, ...
Proceedings of the National Academy of Sciences 105 (29), 9994-9998, 2008
2132008
Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420
N Blondiaux, M Moune, M Desroses, R Frita, M Flipo, V Mathys, ...
Science 355 (6330), 1206-1211, 2017
1382017
Controlling transgene expression in subcutaneous implants using a skin lotion containing the apple metabolite phloretin
M Gitzinger, C Kemmer, MD El-Baba, W Weber, M Fussenegger
Proceedings of the National Academy of Sciences 106 (26), 10638-10643, 2009
1282009
The food additive vanillic acid controls transgene expression in mammalian cells and mice
M Gitzinger, C Kemmer, DA Fluri, M Daoud El-Baba, W Weber, ...
Nucleic acids research 40 (5), e37-e37, 2012
1262012
Dissecting colistin resistance mechanisms in extensively drug-resistant Acinetobacter baumannii clinical isolates
V Trebosc, S Gartenmann, M Tötzl, V Lucchini, B Schellhorn, M Pieren, ...
MBio 10 (4), 10.1128/mbio. 01083-19, 2019
1032019
Functional cross‐kingdom conservation of mammalian and moss (Physcomitrella patens) transcription, translation and secretion machineries
M Gitzinger, J Parsons, R Reski, M Fussenegger
Plant biotechnology journal 7 (1), 73-86, 2009
492009
A novel genome-editing platform for drug-resistant Acinetobacter baumannii reveals an AdeR-unrelated tigecycline resistance mechanism
V Trebosc, S Gartenmann, K Royet, P Manfredi, M Tötzl, B Schellhorn, ...
Antimicrobial agents and chemotherapy 60 (12), 7263-7271, 2016
432016
In vitro activity of rifabutin against 293 contemporary carbapenem-resistant Acinetobacter baumannii clinical isolates and characterization of rifabutin mode of …
V Trebosc, B Schellhorn, J Schill, V Lucchini, J Bühler, M Bourotte, ...
Journal of Antimicrobial Chemotherapy 75 (12), 3552-3562, 2020
272020
Composition for treatment of tuberculosis
R Schoenmakers, W Weber, M Gitzinger, M Fussenegger, M Tigges, ...
US Patent 8,912,329, 2014
232014
Phenylethyl butyrate enhances the potency of second-line drugs against clinical isolates of Mycobacterium tuberculosis
T Grau, P Selchow, M Tigges, R Burri, M Gitzinger, EC Böttger, ...
Antimicrobial agents and chemotherapy 56 (2), 1142-1145, 2012
212012
A fragment-based approach towards the discovery of N-substituted tropinones as inhibitors of Mycobacterium tuberculosis transcriptional regulator EthR2
H Prevet, M Moune, A Tanina, C Kemmer, A Herledan, R Frita, ...
European journal of medicinal chemistry 167, 426-438, 2019
162019
The small-molecule SMARt751 reverses Mycobacterium tuberculosis resistance to ethionamide in acute and chronic mouse models of tuberculosis
M Flipo, R Frita, M Bourotte, MS Martínez-Martínez, M Boesche, GW Boyle, ...
Science Translational Medicine 14 (643), eaaz6280, 2022
132022
The Role of OmpR in Bile Tolerance and Pathogenesis of Adherent-Invasive Escherichia coli
V Lucchini, A Sivignon, M Pieren, M Gitzinger, S Lociuro, N Barnich, ...
Frontiers in Microbiology 12, 684473, 2021
102021
Design and synthesis of water-soluble prodrugs of rifabutin for intraveneous administration
K Antraygues, M Maingot, B Schellhorn, V Trebosc, M Gitzinger, B Deprez, ...
European Journal of Medicinal Chemistry 238, 114515, 2022
62022
Rifabutin for infusion (BV100) for the treatment of severe carbapenem-resistant Acinetobacter baumannii infections
V Trebosc, C Kemmer, S Lociuro, M Gitzinger, GE Dale
Drug Discovery Today 26 (9), 2099-2104, 2021
62021
Composition for treatment of tuberculosis
R Schoenmakers, W Weber, M Gitzinger, M Fussenegger, M Tigges, ...
32010
Targeting virulence regulation to disarm Acinetobacter baumannii pathogenesis
V Trebosc, V Lucchini, M Narwal, B Wicki, S Gartenmann, B Schellhorn, ...
Virulence 13 (1), 1868-1883, 2022
22022
In vivo efficacy of BV100 in mouse models of Acinetobacter baumannii infections
GE Dale, C Kemmer, V Trebosc, B Schellhorn, M Gitzinger, S Lociuro, ...
ECCMID 2021 congress, 2021
22021
Structure-activity relationships of actively FhuE transported rifabutin derivatives with potent activity against Acinetobacter baumannii
M Maingot, M Bourotte, AC Vetter, B Schellhorn, K Antraygues, H Scherer, ...
European Journal of Medicinal Chemistry 252, 115257, 2023
12023
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20